Firm News

Home 9 News Item 9 Wiggin and Dana Represents Client Affibody AB in its Collaboration with Inmagene Biopharmaceuticals Ltd.

Wiggin and Dana Represents Client Affibody AB in its Collaboration with Inmagene Biopharmaceuticals Ltd.

May 15, 2020

On behalf of the Firm, Wiggin and Dana Partner Patti Melick and Associate Madeleine Tavcar represented client Affibody AB in its license and collaboration agreement with Inmagene Biopharmaceuticals Ltd. to develop and commercialize Affibody’s product, ABY-035 in several major Asian markets. Currently in Phase 2 development, ABY-035 is a bispecific molecule targeting Interleukin-17A (IL-17), for multiple auto-immune diseases.  Under the terms of the agreement, Affibody received a $10 million upfront payment and is eligible to receive up to $215.5 million in additional regulatory and sales milestones, plus royalties on sales in such Asian markets. Additionally, Inmagene will share the global development costs of select clinical trials and be eligible to receive payments and royalties from Affibody relating to certain global development and commercialization milestones in select indications. Affibody retained global development and commercialization rights in the markets not covered by this Agreement.

To learn more, click here.

Resources

Related People

Related Services

Firm Highlights